Share This Page
Suppliers and packagers for generic pharmaceutical drug: brensocatib
✉ Email this page to a colleague
brensocatib
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Insmed Inc | BRINSUPRI | brensocatib | TABLET;ORAL | 217673 | NDA | Insmed Incorporated | 71558-001-30 | 30 TABLET in 1 BOTTLE (71558-001-30) | 2025-08-12 |
| Insmed Inc | BRINSUPRI | brensocatib | TABLET;ORAL | 217673 | NDA | Insmed Incorporated | 71558-002-30 | 30 TABLET in 1 BOTTLE (71558-002-30) | 2025-08-12 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Brensocatib
Introduction
Brensocatib, a potent and selective inhibitor targeting dipeptidyl peptidase-1 (DPP-1), is primarily developed for treating inflammatory diseases such as bronchiectasis and other respiratory conditions. As a novel therapeutic agent, the sourcing and supply chain for brensocatib are critical components impacting its commercialization and accessibility. This analysis explores the landscape of suppliers involved in the development, manufacturing, and distribution of brensocatib, emphasizing key industry players, manufacturing considerations, and the strategic implications for stakeholders.
Overview of Brensocatib and Its Development
Brensocatib, developed by Insmed Incorporated, entered clinical trials as an innovative approach to modulate neutrophil activity by inhibiting DPP-1, an enzyme responsible for activating neutrophil serine proteases. The drug demonstrates promising therapeutic potential, especially in managing bronchiectasis and other airway inflammatory conditions [1].
Given its status as an investigational and emerging drug candidate, the supply chain for brensocatib involves several stages — from active pharmaceutical ingredient (API) synthesis to formulation and distribution. These stages depend on specialized suppliers with capabilities in complex chemical synthesis, manufacturing of biologically active compounds, and stringent quality control.
Active Pharmaceutical Ingredient (API) Suppliers
The core component of brensocatib production is its API, which requires high precision in chemical synthesis under Good Manufacturing Practice (GMP) standards. While specific API suppliers for brensocatib are not publicly disclosed due to confidentiality and strategic reasons, several industry players and contract manufacturing organizations (CMOs) are likely involved.
-
Contract Manufacturing Organizations (CMOs):
Many biotech firms collaborating with pharmaceutical companies for API synthesis partner with CMOs specializing in complex APIs for respiratory drugs. These CMOs often possess advanced chemical synthesis platforms, enabling scaling from early-phase trials to commercial production while maintaining compliance. -
Key Players in API Production:
- Lonza Group: Known for its extensive portfolio in semi-synthetic and synthetic APIs, Lonza provides manufacturing capabilities for small molecules in the respiratory space.
- Samsung Biologics and FujiFilm Diosynth: Although more prominent in biologics, these firms also offer chemical APIs.
- WuXi AppTec: A global player with manufacturing expertise for small-molecule APIs, capable of scaling to commercial quantities while adhering to GMP standards.
These companies operate with high secrecy regarding specific client projects, including brensocatib, to maintain competitive advantage.
Formulation and Finished Dosage Form Suppliers
Post-API synthesis, the manufacturing of the finished drug involves formulation, encapsulation, and packaging. Suppliers undertaking these operations are often affiliated with the original development biotech or contract manufacturing partners.
- Contract Packagers and Fill-Finish Companies:
Firms such as Catalent and Alfasigma are leaders in providing formulation, fill-finish, and packaging services for specialized drugs, including oral tablets or capsules possibly envisaged for brensocatib.
Distribution and Supply Chain Logistics
Once manufactured, the distribution network for brensocatib involves global and regional logistics providers capable of handling sensitive pharmaceutical products. Temperature-controlled shipping, real-time tracking, and regulatory compliance are essential components.
- Key Logistics Providers:
- UPS Healthcare
- DHL Medical Express
- FedEx Healthcare
They work in concert with regulatory bodies to ensure the integrity and timely delivery of APIs and finished products.
Strategic and Regulatory Considerations
The supply chain for brensocatib is heavily regulated, as disruptions can impact clinical trials and time-to-market. Suppliers must comply with international standards, including FDA's cGMP, EMA guidelines, and ICH quality standards.
- Impact of Supply Chain Disruptions:
Any interruption — due to geopolitical issues, raw material shortages, or manufacturing delays — could significantly impede development timelines and product availability. Strategic partnerships and dual sourcing are common risk mitigation strategies.
Emerging Trends and Future Outlook
As development progresses, Insmed and its partners may seek more diversified and geographically dispersed suppliers to mitigate risks and optimize global supply. Additionally, with potential commercialization, establishing manufacturing capabilities within key markets (e.g., U.S., Europe, Asia) becomes critical.
Advances in synthetic chemistry and bioprocessing may influence future supplier capabilities, emphasizing flexibility, scalability, and sustainability.
Key Takeaways
- Major API suppliers for brensocatib are likely specialized CMOs with expertise in small-molecule synthesis under GMP conditions, including firms such as Lonza, WuXi AppTec, and FujiFilm Diosynth.
- Formulation and packaging involve leading contract manufacturers like Catalent or Alfasigma, supporting scalable and compliant production.
- Distribution logistics rely on global healthcare logistics providers ensuring product integrity and regulatory compliance.
- Supply chain resilience hinges on diversification, adherence to international quality standards, and strategic partnerships to mitigate disruptions.
- Future supply chain developments may include regional manufacturing hubs and advancements in chemical synthesis technologies.
FAQs
-
Who are the primary API suppliers for brensocatib?
While not publicly confirmed, leading API manufacturers such as Lonza, WuXi AppTec, and FujiFilm Diosynth are potential providers due to their expertise in small-molecule synthesis for respiratory drugs. -
Are there any exclusive agreements with suppliers for brensocatib?
Details regarding exclusive supply agreements are proprietary and not publicly disclosed, but strategic alliances often exist to secure supply and ensure compliance. -
What challenges exist in sourcing brensocatib’s raw materials?
Sourcing complex chemical precursors may face issues like raw material shortages, geopolitical factors, and regulatory hurdles, impacting overall supply continuity. -
How does Insmed ensure the quality of its supply chain for brensocatib?
Insmed adheres to strict cGMP standards, conducts comprehensive supplier qualification, and implements robust quality assurance protocols across its supply chain. -
What are future prospects for expanding brensocatib’s manufacturing capacity?
As clinical trials progress towards commercialization, partnerships with regional manufacturing hubs and technology advances may facilitate increased production capacity and global accessibility.
References
[1] Insmed Incorporated. (2023). Brensocatib Clinical Development Update. Retrieved from [Insmed’s official website].
[2] U.S. Food and Drug Administration. (2022). Good Manufacturing Practice (GMP) Regulations.
[3] Contract Manufacturing Organizations. (2023). API Manufacturing Capabilities for Respiratory Drugs. Industry Reports.
More… ↓
